ºìÁì½í¹Ï±¨

This analysis examines Huntington disease (HD) in long-term care (LTC) and clinic settings, including drugs prescribed to LTC residents with HD

Learn about Huntington disease (HD) in long-term care (LTC) and clinic settings, including drugs prescribed to LTC residents with HD.

Cystic fibrosis is a genetic disease affecting the lungs and other internal organs. This analysis looks at the impact of Trikafta on health system use.

Learn about the impact of Trikafta on the health system use of patients with cystic fibrosis.

ºìÁì½í¹Ï±¨is working to improve the collection and use of real-world evidence about drugs for rare diseases as part of the National Strategy for Drugs for Rare Diseases.

An overview of Canadian health spending trends, featuring comparative expenditure data at provincial, territorial and international levels.

This report highlights some key considerations to support those using ºìÁì½í¹Ï±¨data for analyses of drugs for rare diseases and explores opportunities to improve data to support these analyses.

This report explores client characteristics, services provided in CHCs, use of acute and ambulatory care, and prescription drug use among CHC primary care clients.

This report summarizes information about prescription drug data in Canada (assets, needs, gaps, limitations and opportunities) by jurisdiction.

Take an in-depth look at prescribed drug spending in Canada in 2022 and learn about how different drug classes contribute to current trends in total public drug program spending.